Condition: Gastroenteropancreatic Neuroendocrine Tumor · Radiotherapy · Sponsor: Assistance Publique - Hôpitaux de Paris
Operandi project aims to address unmet clinical needs in the current management of GEP-NETs treated with PRRT by exploring new opportunities provided by imaging-based (AI algorithms) and data augmentation, simultaneous 68Ga-DOTATOC PET-MRI imaging, and novel approaches to increase patient selection and PRRT efficacy (genomic profiling, radiopotentiators, and new radionuclides). The study aim to identify predictive and early markers indicative of PRRT effectiveness based on a large prospective cohort of GEP-NET patients. This cohort will be used to uncover relevant predictive signatures within the morphological, functional, and molecular imaging data using novel imaging-based AI approaches with a new patient imaging pathway including simultaneous 68Ga-DOTATOC PET-MRI. Considering this global objective, the objective of this clinical research protocol is to provide clinical, molecular and imaging data in a prospective standardized study, notably by performing systematic PET-MRI at baseline, at mid course of PRRT and 1 year after PRRT initiation, in patients with advanced GEP-NETs treated with PRRT.
This description comes directly from the study's public registry record.
Catherine ANSQUER · 00-33-2-40-08-41-36 · catherine.ansquer@chu-nantes.fr
Louis DE MESTIER · 00-33-1-40-87-53-28 · louis.demestier@aphp.fr
Always discuss trial participation with your own doctor first.
| Médecine nucléaire et Biophysique - Beaujon | Clichy, France | Recruiting |
| Pancréatologie et Oncologie Digestive - Beaujon | Clichy, France | Recruiting |
| Hépato-gastro-entérologie, cancérologie digestive et assistance nutritionnelle - CHU Nantes | Nantes, France | Active Not Recruiting |
| Médecine nucléaire - CHU Nantes | Nantes, France | Recruiting |
| Service de Médecine Nucléaire, Groupe Hospitalier Bichat-Claude Bernard | Paris, France | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06256705